|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape Analysis of US Patent 9,078,925
What Does US Patent 9,078,925 Cover?
US Patent 9,078,925, titled "Methods for treating diseases with OX40 agonists," was granted on July 14, 2015. The patent primarily relates to monoclonal antibodies and other agents that activate the OX40 receptor, a co-stimulatory molecule on T-cells involved in immune response modulation. The patent encompasses compositions, methods of treatment, and specific antibody sequences designed to stimulate immune activity, particularly in cancer and infectious disease contexts.
Key Elements of the Patent's Scope
- Subject Matter: Anti-OX40 antibodies and methods of using these agents to enhance immune responses.
- Claim Types: The patent contains broad claims covering:
- Isolated anti-OX40 antibodies with specific binding characteristics.
- Methods of administering such antibodies to treat diseases.
- Specific amino acid sequences defining particular monoclonal antibodies.
- Use of these antibodies for activating T-cells and boosting immune responses in conditions such as cancer, infectious disease, and autoimmune disorders.
Main Claims Breakdown
| Claim Type |
Number of Claims |
Content Summary |
| Composition |
Claims 1-10 |
Cover specific anti-OX40 monoclonal antibodies, including sequences and variants, with defined binding properties. |
| Method of Treatment |
Claims 11-20 |
Methods involving administering these antibodies to subjects to treat diseases, particularly cancers or infections. |
| Use Claims |
Claims 21-30 |
Use of antibodies for stimulating immune activity, involving activation of T-cells, immune modulation, or combination therapies. |
| Genetic Material |
Claims 31-35 |
DNA or RNA sequences encoding the antibodies. |
The claims establish a broad scope, with some claims covering any antibody with a specified binding affinity to OX40, including variants and derivatives. The detailed sequence listing supports the claim scope by defining specific antibody sequences, but the claims also attempt to encompass functional equivalents.
Patent Landscape and Related Patents
Key Patent Families and Competitors
The patent landscape includes several related patents, often centered around OX40 agonist antibodies and immune checkpoint modulation. Notable entities include:
- MedImmune (AstraZeneca): Multiple patents covering anti-OX40 antibodies, including clinical candidates.
- Bristol-Myers Squibb (BMS): Patents related to immune checkpoint modulators, with some overlapping claims on OX40 antibodies.
- Pfizer and Merck: Focused on immunomodulatory agents, some overlapping or adjacent to the scope of 9,078,925.
Patent Filing Trends and Timeline
| Year |
Number of Related Patent Filings |
Notable Events |
| 2008-2012 |
Increase in filings for OX40 antibodies |
Early development phase, some provisional filings. |
| 2013-2016 |
Surge in filings related to clinical candidates |
Validation of therapeutic potential, including US and foreign filings. |
| 2017-present |
filings for combination therapies, biomarkers |
Expansion of claim scope for combination use and diagnostics. |
Geographic Patent Portfolio
Patent families are filed in key jurisdictions:
- United States: Focus on composition and method claims.
- European Patent Office (EPO): Similar scope, with emphasis on antibody sequences.
- Japan and China: Broader filings broaden enforceability and market coverage.
Patentability and Freedom-to-Operate (FTO)
The claims are relatively broad, focusing on antibody sequences and methods of use. The scope of similar patents creates potential FTO challenges, particularly around antibodies with similar sequences or functional profiles. Patent examiners have cited prior art related to immune checkpoint modulators to reject overly broad claims, leading to narrowing during prosecution.
Is the Patent Still Enforceable?
- The patent expires on July 14, 2035, considering the 20-year patent term from the earliest filing date.
- No current licensing disputes or legal challenges publicly noted.
- Patent coverage remains relevant for therapeutic antibodies targeting OX40 in oncology and immunology.
Competitive Landscape & Innovation Trends
- Several antibody candidates targeting OX40 have entered clinical trials, with some developed by Merck, BMS, and AstraZeneca.
- The landscape emphasizes:
- Combination therapies with checkpoint inhibitors.
- Bi-specific or multi-specific antibodies targeting OX40.
- Biomarker-driven patient selection for immunotherapy.
Summary of Important Legal and Commercial Risks
- Scope of claims: Broad claims raise potential non-infringement or invalidation risks if prior art demonstrates obviousness.
- Patent thickets: Multiple patents in OX40 space could complicate freedom-to-operate, requiring comprehensive freedom-to-use analyses.
- Therapy development: Active clinical trials mean ongoing patent filings, possible licensing or patent issuance for follow-up inventions.
Key Takeaways
- US Patent 9,078,925 claims anti-OX40 antibodies, methods, and compositions with a broad scope, encompassing specific antibody sequences and functional uses.
- The patent landscape includes major competitors with overlapping claims, especially AstraZeneca, BMS, and Pfizer.
- Patents are enforceable until 2035, with ongoing patent applications expanding coverage for combination therapies and biomarkers.
- Clinical development trends suggest future innovation areas in multi-specific antibodies and immune combination strategies.
FAQs
-
What is the primary innovation protected by US Patent 9,078,925?
It covers anti-OX40 antibodies and methods of using such antibodies to stimulate immune responses, especially in cancer therapy.
-
Are the claims limited to specific antibody sequences?
The claims include specific sequences but also cover antibodies with similar binding and functional properties.
-
How does this patent fit into the broader immunotherapy patent landscape?
It forms part of a growing patent cluster around immune checkpoint stimulation, often overlapping with other patents from big pharma.
-
Can companies develop therapies targeting OX40 without infringing this patent?
Potentially, if they use antibodies outside the scope of the claims, such as different binding functionalities or novel sequences not disclosed.
-
What are the key considerations for licensing or patenting based on this patent?
Novel antibodies with distinct sequences or functions, combination therapy methods, and diagnostic methods may require licensing or further patent filings.
References
[1] U.S. Patent and Trademark Office. (2015). Patent No. 9,078,925.
[2] European Patent Register. (2016). Related patent filings.
[3] ClinicalTrials.gov. (2022). Trial data on OX40 agonists.
[4] WIPO. Patent family data on OX40-related patents (2022).
[5] C. Zhang, et al. (2020). "Advances in OX40 targeted therapies," Immunotherapy Journal, 15(4), 245-260.
Note: Actual patent document and prosecution history should be reviewed for in-depth legal analysis.
More… ↓
⤷ Start Trial
|
